Pharma giants place big bets with direct investments in China market

Recently, pharmaceutical powerhouses Roche and Bayer announced layoff plans, but at the same time they – along with other big names such as Eli Lilly, Novo Nordisk, and Sanofi-aventis – increased investments in China. Roche will cut 4,800 positions worldwide but increase its Chinese headcount by 25%...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Sinopec announces plans to become China's largest hydrogen energy company in response to China's 14th Five-Year Plan

News Commentary | March 18, 2021

One of Lux's top predictions for 2021 was that China would triple global green hydrogen capacity by 2025. While it remains to be seen where Sinopec plans to fit in China's hydrogen economy, it will start by building 1,000 hydrogen fueling stations by 2025. Lofty claims are common from China, ... To read more, click here.

Why your company may want to follow Bill Gates' Breakthrough Energy and join InvestEU to accelerate commercialization of "climate-smart" technology

Analyst Insight | June 11, 2021

A unique opportunity to de‑risk deployment and scaling of new "green" technology The EU and Bill Gates announced a new partnership this week. They established a new joint investment fund, called Catalyst, with target capital of €820 million ($1 billion). The fund is an investment vehicle designed... Not part of subscription

Novo Nordisk looks beyond diabetes in its most recent therapeutic program acquisition

News Commentary | July 13, 2021

Novo Nordisk has mostly focused on diabetes care. Hence, this latest acquisition for the treatment of a rare heart disease known as ATTR cardiomyopathy seems out of character. However, the company has been building a pipeline of drug assets in the rare diseases category, starting with hemophilia and... Not part of subscription